Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8342)	1/17/1999 9:53:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, you have done a lousy job of explaining the total number disaster! I know you don't like talking about it but could the trial of had an early halt due to excellent efficacy if the total number of deaths not met? It is my understanding that trial COULD NOT be halted due to excellent efficacy if it had it because mortality number was not reached. Yes indeed, in my opinion that means Neuprex could of had excellent efficacy, overwhelming efficacy if you will last Sept DSMB but total number of deaths not met so the dying must continue. BTW, it looks like Shaman is going to FDA with a p of .075 on their antidiarrhea product.